Meeting
2017 ASCO Annual Meeting
Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.
Authors
Jorge E. Cortes
The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
Jorge E. Cortes , Andreas Hochhaus , Hagop M. Kantarjian , François Guilhot , Vamsi K. Kota , Timothy P. Hughes , Suresh Shelat , Li Li , Elias Jabbour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT00481247
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7051)
DOI
10.1200/JCO.2017.35.15_suppl.7051
Abstract #
7051
Poster Bd #
251
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.
First Author: H. Kantarjian
Poster
2021 ASCO Annual Meeting
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
First Author: Tim H. Brümmendorf
Poster
2011 ASCO Annual Meeting
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes.
First Author: P. Laneuville
Poster
2014 ASCO Annual Meeting
One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.
First Author: James E. Signorovitch